9-Oct-2018
European Pharmaceutical Manufacturer
Patients may need to wait an extra five or 10 years to access generic medicines, which could raise healthcare costs by as $100 billion over the next five years, according to the latest CPhI annual report
5-Oct-2018
Financial Post
Experts are fuming, saying USMCA will hamper Canada’s innovation economy and hike costs to the health care system over patented drugs.
28-Aug-2018
Pharmaceutical Commerce
The 10-year span is more than what had existed before but the biopharma industry has long argued for the same 12-year exclusivity that exists for biologics within the US market.
19-Jun-2018
Sydney Morning Herald
Trade Minister Steven Ciobo has promised to take a hard line with Europe on the question of cheap medicines and his counterpart Cecilia Malmström foresees “difficult” negotiations over Australian producers using European names such as "parmesan".
11-Apr-2018
MSF Access Campaign
Officials from the European Union (EU) and India are expected to meet in Brussels on April 12th to resume technical talks on the long-stalled EU-India free trade agreement (FTA). A leaked draft of the agreement, which has been under discussion since 2007, contains proposals from the EU that push for intellectual property (IP) provisions in the FTA that could jeopardize access to affordable medicines.
29-Mar-2018
Public Citizen
NAFTA was the first “trade” agreement that included new monopoly powers for Big Pharma companies.
12-Feb-2018
East Asia Forum
Japan’s role in RCEP negotiations appears to have been shaped by its participation in the TPP. Japan is now championing for expanded intellectual property right provisions which may block access to affordable medicines